Viewing nowCombinationTrinam 2.5/1000 mg (Linagliptin, Metformin)
Linagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
DaiWoong Bio Co., Ltd.

MFDS item code 202401052 · Approved 2024.04.30
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes manage their blood sugar more effectively. It is used to improve blood sugar levels through the combined action of linagliptin and metformin, while adhering to dietary and exercise regimens. Therefore, it is a suitable treatment option for those who find it challenging to manage their blood sugar.
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current dose of metformin (for example, a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). Studies evaluating the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication helps regulate blood sugar levels. However, caution is necessary as rare complications, such as lactic acidosis, may occur when taking this medication. If severe abdominal pain, muscle pain, weakness, or difficulty breathing arises, consultation with a physician should be sought immediately. This medication should not be used by patients with impaired kidney function, liver dysfunction, severe infections, or dehydration. It is also advisable for pregnant or breastfeeding women to avoid taking this medication. Since hypoglycemia may occur, it is important to frequently check blood sugar levels, especially when taken with other hypoglycemic agents or insulin. Excessive alcohol consumption should also be avoided for safety. This medication should be taken with regular kidney function checks, and if there are situations where kidney function may suddenly worsen, temporary discontinuation should occur. If iodinated contrast agents are used in radiological examinations, discontinuation of this medication is also required until kidney function stabilizes. Rarely, adverse effects such as pancreatitis or blistering disorders like bullous pemphigoid may occur, so immediate notification to a physician is essential if severe abdominal pain or skin lesions appear. This medication may lower vitamin B12 levels, so if used for a prolonged period, monitoring for vitamin B12 deficiency is advised with supplementation if necessary. Elderly patients may require adjustment of dosage and regular monitoring of kidney function since kidney function can decline. It is not recommended for use in children under 10 years of age. The impact on driving or operating machinery is unclear, but caution is advised due to potential hypoglycemic symptoms. In cases of overdose, gastrointestinal symptoms or lactic acidosis may occur, and immediate medical attention should be sought. Store this medication in a place out of reach of children and avoid moisture.
Lactic acidosis, hypoglycemia, taste disturbances, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, severe arthralgia accompanied by disability, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscal injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, pneumonia, hypertension, pruritus, insomnia, depression, anxiety, contusion, bone contusion, concussion, fracture, hand fracture, laceration, palpitations, dry eye, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hearing loss, erectile dysfunction, thyroid enlargement, confusion, nocturia, dermatitis
Not everyone experiences these, and they can vary from person to person.
Store this medication in a sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.
Pink, oval, biconvex, film-coated tablet
30 tablets/bottle, 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
DaiWoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.